XenaCare Holdings Announces Availability of Cobroxin through the Chain Drug Marketing Association (CDMA)

XenaCare Holdings has Announced That the Chain Drug Marketing Association (CDMA)
Will Begin Taking Inventory of Cobroxin for Redistribution and Sale Through its
6,000 Member Pharmacies
DELRAY BEACH, Fla.--(Business Wire)--
XenaCare Holdings, Inc. (OTCBB: XCHO), a company specializing in the marketing
and retail distribution of consumer healthcare products, has announced today
that the Chain Drug Marketing Association (CDMA) will begin inventorying
Cobroxin for redistribution to its member pharmacies. The CDMA currently has
over 6,000 independent pharmacy members throughout the United States.

"As one of the largest pharmacy organizations in the United States, we are
excited to be working with the CDMA to distribute Cobroxin to its independent
pharmacy members," explained Frank Rizzo, President of XenaCare Holdings.
"Having a presence in CDMAmember pharmacies will help us build significant
awareness about Cobroxin as we continue to expand the brand nationwide through
retailers and our multimillion dollar national advertising campaign," he
concluded.

Cobroxin is the first over-the-counter (OTC) pain reliever clinically proven to
treat moderate to severe (Stage 2) chronic pain. The drug is available as an
oral spray for treating lower back pain, migraines, neck aches, shoulder pain,
cramps and neuralgia and as a topical gel for treating joint pain and pain
associated withrepetitive stress and arthritis.

Additional benefits to Cobroxin include:

* All Natural
* Non-Addictive
* Non-Narcotic
* Non-Opiate
* More Potent than Morphine
* Long Lasting

XenaCare Holdings, which holds the exclusive license from Nutra Pharma
Corporation (OTCBB: NPHC) to market and distribute Cobroxin in the United
States, announced in October that it had begun accepting orders for Cobroxin
online at Cobroxin.com. Additionally, the Company has recently begun
distribution to online and brick-and-mortar retailers and will continue to
announce locations where Cobroxin will be available for sale.

About XenaCare Holdings

XenaCare Holdings, Inc. engages in the formulation, marketing, and distribution
of nutrition supplement products primarily in the United States. In addition to
Cobroxin for the treatment of moderate to severe (Stage 2) chronic pain, the
Company`s clinical products include XenaCor, which supports the lowering of
serum cholesterol, C-reactive protein, and homocysteine levels to support
cardiovascular health; XenaTri for lowering triglycerides and raising HDL to
support cardiovascular health; and XenaZyme Plus that increases the body`s
oxygen carrying capacities designed to support digestion. XenaCare`s clinical
products also comprise body replenishment products. In addition, the company
offers formulations for the lifestyle performance market, which consists of
sports line for athletes, including SunPill that is formulated to protect the
skin when exposed to damaging ultraviolet rays. XenaCare markets its products
through the Internet, pharmacies, and doctors offices. The company was founded
in 2001 and is based in Delray Beach, Florida.

http://www.XenaCareHoldings.com
http://www.Cobroxin.com

Cautionary Note Concerning Forward Looking Statements

Except for the historical and present factual information contained herein, the
matters set forth in this document, including statements regarding our plans to
introduce Cobroxin into the commercial marketplace and for additional marketing
campaigns are forward looking statements. Although these forward looking
statements constitute our current plans, the timing, marketing channels and
advertising support for the product may change. Investors are cautioned that
these forward-looking statements are not guarantees of future performance.
Actual events or results may differ from the Company`s current plans. There are
many risks, uncertainties and other factors that can prevent the achievement of
our goals or cause results to differ from those expressed or implied by these
forward-looking statements including, without limitation, the risks described in
greater detail in filings made by the Company with the Securities and Exchange
Commission. The Company assumes no obligation to publicly update or revise its
forward-looking statements even if experience or future events make it clear
that any of the anticipated results expressed or implied herein will not be
realized. The Company's filings may be accessed at the SEC's Edgar system at
www.sec.gov.

XenaCare Holdings
Frank Rizzo, 561-497-6676
frizzo@xenacare.com

Copyright Business Wire 2009